Cytokinetics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Cytokinetics sits in the top decile of US sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count).
Cytokinetics: 31 sponsored US clinical trials, 3 recruiting.
Cytokinetics sponsors 31 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 22 completed. 10 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Heart Failure, with 2 trials.
Top-decile sponsor footprint
Cytokinetics ranks in the top decile of sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
22 of 27 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
31 total, page 1 of 1
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
NCT06793371
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
NCT06081894
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT05767346
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
NCT05924815
A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants
NCT05877053
A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants
NCT05662215
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
NCT05442775
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05186818
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT04944784
Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
NCT04219826
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
NCT03759392
A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects
NCT03767855
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03160898
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
NCT02929329
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
NCT02936635
A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
NCT02644668
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
NCT02496767
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
NCT01786512
Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency
NCT01737866
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
NCT01709149
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01486849
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01378676
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
NCT01300013
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
NCT01268280
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
NCT01131013
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01089010
Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
NCT00748579
A Study of CK-1827452 Infusion in Stable Heart Failure
NCT00624442
A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma
NCT00343564
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 15 |
| Phase 3 | 10 |
Therapeutic Areas
What is open in the Cytokinetics pipeline
3 recruiting of 31 indexed (10% open); 22 completed (71%).
Phase mix: 10 late (III/IV) vs 21 early (I/II) (early-phase heavy).
Top condition: Heart Failure (2 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Cytokinetics: open-pipeline peers nationwide
Peers matched on 31 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Cytokinetics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 31 trials (± recruiting share)
- Children's Hospitals and Clinics of Minnesota · 31 trials · 10% recruiting
- Cook Group Incorporated · 31 trials · 0% recruiting
- Halozyme Therapeutics · 31 trials · 3% recruiting
- Insmed Incorporated · 31 trials · 6% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Sanofi · 10% recruiting · 713 trials
- Children's Oncology Group · 10% recruiting · 342 trials
- University of North Carolina, Chapel Hill · 10% recruiting · 1,109 trials
- Joslin Diabetes Center · 10% recruiting · 73 trials
Related
What to do with this Cytokinetics page
31 registered trials is a research-attention snapshot, not an endorsement of Cytokinetics or any single study.
- 3 of Cytokinetics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Heart Failure is the condition Cytokinetics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Heart Failure trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Cytokinetics pipeline card: 31 registered trials from official public datasets.Report a data error.